Rivaroxaban Faces Uphill Battle At FDA Advisory Panel

The third time may not be the charm. Twice before the FDA has turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (rivaroxaban). On Thursday the Cardiovascular and Renal Drugs Advisory Committee will take up the sNDA yet again, but FDA review documents posted today suggest that the company will again face an uphill battle.

Click here to read the full post on Forbes.

 

Stone wall of an English barn

 

Leave a Reply

%d bloggers like this: